Skip to main
AVXL
AVXL logo

AVXL Stock Forecast & Price Target

AVXL Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anavex Life Sciences Corp has made significant advancements in its clinical pipeline, particularly with ANAVEX 3-71, which has shown promising Phase 2 results in schizophrenia, indicating a robust platform for treating central nervous system diseases. The company ended fiscal 2025 with approximately $102.6 million in cash, reflecting a modest increase, which positions it well for continued investment in clinical development. Additionally, encouraging efficacy measures and reductions in neuroinflammatory biomarkers suggest potential therapeutic benefits, which, along with a reduced forecasted net loss for fiscal 2026, may enhance investor confidence in the company’s future prospects.

Bears say

Anavex Life Sciences Corp reported a net loss of $0.54 per share, indicating ongoing financial challenges despite a decrease in research and development expenses to $7.3 million from $11.6 million in the prior year, reflecting lower clinical activity. The company faced a significant setback with the recent negative trend vote on the Marketing Authorization Application for its candidate blarcamesine, which reduces the likelihood of gaining crucial regulatory approvals in Europe. Additionally, projections indicate a full-year fiscal 2025 net loss of $0.56 per share, compounded by increased risks associated with clinical data setbacks, potential launch failures, and the dilution risk stemming from ongoing capital needs.

AVXL has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anavex Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anavex Life Sciences (AVXL) Forecast

Analysts have given AVXL a Strong Buy based on their latest research and market trends.

According to 2 analysts, AVXL has a Strong Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anavex Life Sciences (AVXL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.